Publications by authors named "E G Elisabeth de Vries"
Purpose: Preclinical studies suggest that trimebutine could be a potential treatment for glioblastoma. The aim of this study was to investigate the distribution, kinetics and tumor accumulation of [C]trimebutine.
Method: A proliferation assay and cell scratch healing assay were performed to confirm the antitumor effects of trimebutine on C6 glioma cells in-vitro.
Multiple sclerosis (MS) is a neurodegenerative disease characterized by demyelinated lesions in the brain and spinal cord. A few clinical studies using PET to image myelin in the brain have been performed, but none investigated the spinal cord. Because clinically relevant motor symptoms are primarily due to spinal cord damage, this translational study evaluated [C]-methyl-4,4'-diaminostilbene (MeDAS) as a PET tracer for myelin imaging in the rat and human spinal cord.
View Article and Find Full Text PDFIncreased dopamine D/D receptor and serotonin transporter availability in male rats after spontaneous remission from repeated social defeat-induced depression; a PET study in rats.
Neurobiol Dis
November 2024
Most pharmacological treatments for depression target monoamine transporters and about 50 % of treated patients attain symptomatic remission. Once remission is attained, it is hard to distinguish the changes on brain monoaminergic transmission induced by the antidepressants, from those associated to remission per se. In this study, we aimed at studying the brain of spontaneously remitted rats from repeated social defeat (RSD)-induced depression in terms of dopamine D/D receptor and serotonin transporter (SERT) availability, showing absence of depressive symptoms 2 weeks after RSD.
View Article and Find Full Text PDFArticle Synopsis
- The ZEPHIR clinical trial aimed to assess how [89Zr]trastuzumab-PET/CT and [18F]FDG-PET/CT can predict outcomes in patients with advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1).
- Researchers integrated imaging data from PET/CT scans and gene expression data from biopsy samples to understand the relationship between drug uptake and biological processes in the tumors.
- The study revealed that low uptake of [89Zr]trastuzumab was linked to ECM-related gene pathways, while high uptake correlated with immune responses, highlighting the importance of ECM in affecting drug uptake and treatment response in these patients.
Antibody-drug conjugates (ADC) represent one of the most rapidly expanding treatment modalities in oncology, with 11 ADCs approved by the FDA and more than 210 currently being tested in clinical trials. Spanning over 40 years, ADC clinical development has enhanced our understanding of the multifaceted mechanisms of action for this class of therapeutics. In this article, we discuss key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs.
View Article and Find Full Text PDF